MediWound to Report First Quarter 2025 Financial Results
MediWound Ltd. (NASDAQ: MDWD), a leader in enzymatic therapeutics for tissue repair, has scheduled its first quarter 2025 financial results announcement for Wednesday, May 21, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time following the results release.
Investors can access the call through various channels including toll-free (1-844-676-8833), Israel (1-80-921-2373), and international (1-412-634-6869) numbers. A webcast replay will be available in the Investors section of MediWound's website after the call.
MediWound Ltd. (NASDAQ: MDWD), leader nelle terapie enzimatiche per la riparazione dei tessuti, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per mercoledì 21 maggio 2025. La società terrà una conference call e una webcast alle 8:30 a.m. ora Eastern subito dopo la pubblicazione dei risultati.
Gli investitori potranno accedere alla chiamata tramite diversi numeri, tra cui il numero verde (1-844-676-8833), il numero per Israele (1-80-921-2373) e il numero internazionale (1-412-634-6869). Una registrazione della webcast sarà disponibile nella sezione Investitori del sito web di MediWound dopo la chiamata.
MediWound Ltd. (NASDAQ: MDWD), líder en terapias enzimáticas para la reparación de tejidos, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el miércoles 21 de mayo de 2025. La compañía realizará una llamada conferencia y una transmisión web a las 8:30 a.m., hora del Este tras la publicación de los resultados.
Los inversores pueden acceder a la llamada a través de varios números, incluyendo el gratuito (1-844-676-8833), Israel (1-80-921-2373) e internacional (1-412-634-6869). Una repetición de la transmisión estará disponible en la sección de Inversores del sitio web de MediWound después de la llamada.
MediWound Ltd. (NASDAQ: MDWD)는 조직 복구를 위한 효소 치료제 분야의 선두 기업으로, 2025년 1분기 재무 실적 발표를 2025년 5월 21일 수요일에 예정하고 있습니다. 회사는 실적 발표 후 동부 표준시 오전 8시 30분에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
투자자들은 무료 전화(1-844-676-8833), 이스라엘(1-80-921-2373), 국제 전화(1-412-634-6869) 등 다양한 채널을 통해 콜에 참여할 수 있습니다. 웹캐스트 녹화는 콜 종료 후 MediWound 웹사이트의 투자자 섹션에서 시청할 수 있습니다.
MediWound Ltd. (NASDAQ : MDWD), leader dans les thérapies enzymatiques pour la réparation des tissus, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le mercredi 21 mai 2025. La société organisera une conférence téléphonique et une webdiffusion à 8h30, heure de l'Est après la publication des résultats.
Les investisseurs pourront accéder à l'appel via plusieurs numéros, notamment le numéro vert (1-844-676-8833), Israël (1-80-921-2373) et international (1-412-634-6869). Une rediffusion de la webdiffusion sera disponible dans la section Investisseurs du site web de MediWound après l'appel.
MediWound Ltd. (NASDAQ: MDWD), ein führendes Unternehmen im Bereich enzymatischer Therapeutika zur Gewebereparatur, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Mittwoch, den 21. Mai 2025 geplant. Das Unternehmen wird nach der Veröffentlichung der Ergebnisse eine Telefonkonferenz und ein Webcast um 8:30 Uhr Eastern Time abhalten.
Investoren können die Telefonkonferenz über verschiedene Nummern erreichen, darunter gebührenfreie Nummer (1-844-676-8833), Israel (1-80-921-2373) und international (1-412-634-6869). Eine Aufzeichnung des Webcasts wird nach der Konferenz im Investor-Bereich der MediWound-Website verfügbar sein.
- None.
- None.
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time
YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 21, 2025.
Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates.
Dial-in and call details are as follows:
| Conference Call & Webcast Details | |
| Toll-Free: | 1-844-676-8833 |
| Israel: | 1-80-921-2373 |
| International: | 1-412-634-6869 |
| Webcast: | Click HERE |
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.
For more information, visit www.mediwound.com and follow us on LinkedIn.
| MediWound Contacts: | |
| Hani Luxenburg | Daniel Ferry |
| Chief Financial Officer | Managing Director |
| MediWound Ltd. | LifeSci Advisors, LLC |
| ir@mediwound.com | daniel@lifesciadvisors.com |
| Media Contact: | |
| Ellie Hanson | |
| FINN Partners for MediWound | |
| ellie.hanson@finnpartners.com | |
| +1-929-588-2008 | |
FAQ
When will MediWound (MDWD) release Q1 2025 earnings?
What time is MediWound's Q1 2025 earnings call?
How can I access MediWound's Q1 2025 earnings call?
What does MediWound (MDWD) specialize in?
